TREACE MEDICAL CONCEPTS, INC. TMCI 深 滬
交易中 10-31 11:05:06 美东时间
6.30
-0.050
-0.79%
華盛通- 最 高6.45
- 今 開6.33
- 成交量 2.24万股
- 最 低 6.23
- 昨 收 6.35
- 總市值 3.96亿
- 52周最高 10.79
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 5.155
- 委 比 -38.65%
- 總股本 6290.50万
- 歷史最高 37.17
- 量 比 0.66
- 振 幅 3.46%
- 歷史最低 3.92
- 每 手 1
- 風險率 1.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
Truist Securities Maintains Hold on Treace Medical Concepts, Lowers Price Target to $7
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and lowers the price target from $8 to $7.
10-16 00:03
Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2025 American Orthopaedic Foot & Ankle Society Annual Meeting
Treace Medical Concepts will present its new product innovations, such as Nanoplasty and Percuplasty, and interim data from the ALIGN3D and MTA3D clinical studies at the AOFAS Annual Meeting in Savannah, Georgia. The studies demonstrate low recurrence rates (7.7% at 48 months) and significant pain improvement, supporting Treace’s commitment to advancing bunion surgery.
09-10 11:05
Truist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $8
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and raises the price target from $6.6 to $8.
09-04 20:27
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Treace Medical Concepts Affirms FY2025 Sales Guidance of $224.000M-$230.000M vs $227.030M Est
Treace Medical Concepts (NASDAQ:TMCI) affirms FY2025 sales outlook from $224.000 million-$230.000 million to $224.000 million-$230.000 million vs $227.030 million estimate.
08-08 04:14
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Treace Medical Concepts Announces Peer-Reviewed Publication Of The Four-Year Interim Results From Its Align3d Multicenter Prospective Study Demonstrating Clinical And Radiographic Outcomes Of The Lapiplasty Procedure In The Journal Of Foot & Ankle Surgery
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced
08-06 04:34
Treace Announces Peer-Reviewed Publication of Four-Year Results of the ALIGN3D™ Lapiplasty® Multicenter Prospective Clinical Study
Treace Medical Concepts announced the publication of four-year interim results from its ALIGN3D™ study, showcasing positive outcomes of the Lapiplasty® Procedure for hallux valgus. Results include early return to weight-bearing (7.7 days), low recurrence rates (0.8% HVA>20°), and significant pain reduction (81%) and functional improvement (89%) in patients.
08-05 20:05
Treace to Report Second Quarter 2025 Financial Results on August 7, 2025
<p>Treace Medical Concepts, Inc., a medical technology company, announced it will release second-quarter 2025 financial results on August 7, 2025. A conference call to discuss the results will be held at 4:30 pm ET. Interested investors can register to join the call. The company, which focuses on advanced surgical treatments for bunions and midfoot deformities, also provides updates on its innovative medical devices and systems on its investor re...
07-24 20:05
